Proteins and Peptides

27 Jun 2017 Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH
27 Jun 2017 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
26 Jun 2017 AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
25 Jun 2017 Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial
23 Jun 2017 Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar
23 Jun 2017 FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease
22 Jun 2017 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease
22 Jun 2017 Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes
21 Jun 2017 Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes
19 Jun 2017 Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
17 Jun 2017 Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
15 Jun 2017 Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial
13 Jun 2017 New LEADER analysis shows Victoza® reduces cardiovascular risk in people with type 2 diabetes regardless of severe hypoglycaemia events
13 Jun 2017 Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
13 Jun 2017 ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
13 Jun 2017 Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
12 Jun 2017 Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A
12 Jun 2017 Zealand to regain control of elsiglutide
12 Jun 2017 Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
12 Jun 2017 Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Finland, company expands on development plan
11 Jun 2017 Catalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Meeting
11 Jun 2017 Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions
11 Jun 2017 Merz Neurosciences Announces Positive Phase III Results of Xeomin® (IncobotulinumtoxinA) for Sialorrhea at 2017 MDS Meeting
06 Jun 2017 Refixia® (nonacog beta pegol; N9-GP) approved
05 Jun 2017 Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top